ALNOV.PA
Price:
$0.984
Market Cap:
$58.67M
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segme...[Read more]
Industry
Medical - Devices
IPO Date
2012-10-12
Stock Exchange
EURONEXT
Ticker
ALNOV.PA
According to Novacyt S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -2.14. This represents a change of 123.14% compared to the average of -0.96 of the last 4 quarters.
The mean historical PE Ratio of Novacyt S.A. over the last ten years is -4.86. The current -2.14 PE Ratio has changed 4.30% with respect to the historical average. Over the past ten years (40 quarters), ALNOV.PA's PE Ratio was at its highest in in the December 2021 quarter at 18.80. The PE Ratio was at its lowest in in the June 2021 quarter at -3.95.
Average
-4.86
Median
-3.10
Minimum
-26.75
Maximum
4.51
Discovering the peaks and valleys of Novacyt S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 37.95%
Maximum Annual PE Ratio = 4.51
Minimum Annual Increase = -692.64%
Minimum Annual PE Ratio = -26.75
Year | PE Ratio | Change |
---|---|---|
2023 | -1.54 | -55.40% |
2022 | -3.46 | -87.07% |
2021 | -26.75 | -692.64% |
2020 | 4.51 | -294.67% |
2019 | -2.32 | -32.24% |
2018 | -3.42 | -2.94% |
2017 | -3.53 | 26.75% |
2016 | -2.78 | 37.95% |
2015 | -2.02 | -72.51% |
2014 | -7.33 | -73.26% |
The current PE Ratio of Novacyt S.A. (ALNOV.PA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.58
5-year avg
-5.91
10-year avg
-4.86
Novacyt S.A.’s PE Ratio is less than Biosynex SA (-1.30), less than Biophytis S.A. (-0.05), less than Eurobio Scientific Société anonyme (47.01), greater than Intrasense SA (-4.28), less than Genomic Vision Société Anonyme (-0.01),
Company | PE Ratio | Market cap |
---|---|---|
-1.30 | $47.89M | |
-0.05 | $2.60M | |
47.01 | $241.29M | |
-4.28 | $15.34M | |
-0.01 | $693.19K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novacyt S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novacyt S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Novacyt S.A.'s PE Ratio?
How is the PE Ratio calculated for Novacyt S.A. (ALNOV.PA)?
What is the highest PE Ratio for Novacyt S.A. (ALNOV.PA)?
What is the 3-year average PE Ratio for Novacyt S.A. (ALNOV.PA)?
What is the 5-year average PE Ratio for Novacyt S.A. (ALNOV.PA)?
How does the current PE Ratio for Novacyt S.A. (ALNOV.PA) compare to its historical average?